Core Insights - Bristol Gate Capital Partners emphasizes investing in companies with strong free cash flows, disciplined capital allocation, and high dividend growth for superior risk-adjusted returns [1] - The market has shifted towards AI leaders since late 2022, leading to the fund's underperformance due to narrow breadth, although there is a recent shift supported by the outperformance of dividend-focused indices [1] - The firm's Data Science team's advancements in the Distant Future Model present strong opportunities for investors to buy into the strategy and mitigate risks in a concentrated market [1] Company Focus: Thermo Fisher Scientific Inc. - Thermo Fisher Scientific Inc. is highlighted as a leading contributor in the Q4 2025 investor letter, focusing on life sciences solutions, analytical instruments, specialty diagnostics, and biopharma services [2] - As of March 27, 2026, Thermo Fisher's share price was $473.36, with a one-month return of -6.93% and a 52-week loss of 4.87%, and a market capitalization of $175.846 billion [2] - The company experienced a rally in Q4, reaching a new 52-week high, driven by strong Q3 earnings that exceeded consensus expectations, and anticipates growth in 2026 as headwinds abate [3]

Core Insights - Thermo Fisher Scientific Inc. is a leading life sciences and technology company with a market cap of approximately $193.7 billion, indicating its significant size and influence in the healthcare and diagnostics sectors [1][2] Company Overview - The company develops and supplies scientific instruments, laboratory equipment, specialty diagnostics, reagents, and biopharmaceutical services for research, healthcare, and industrial markets globally [1] - Thermo Fisher has established a dominant presence in research, diagnostics, laboratory equipment, and biopharma services, supported by substantial investments in R&D and strong integrated systems [2] Stock Performance - The stock is currently down 19.9% from its 52-week high of $643.99, reached on January 22, and has decreased 12% over the past three months, underperforming compared to the iShares US Medical Devices ETF, which declined 7.5% in the same period [3] - Year-to-date, the stock is down 11% and has fallen 3.7% over the past 52 weeks, while the IHI ETF has seen a decline of 4.1% in 2026 and 6.8% over the past year [4] Financial Performance - In Q4 2025, the company reported revenue of approximately $12.2 billion, reflecting a 7% year-over-year growth, and adjusted EPS of $6.57, an 8% increase, surpassing Wall Street estimates [6] - Full-year revenue for 2025 grew by 4% to around $44.6 billion, indicating solid earnings despite cautious guidance from the company [6]

Core Insights - Thermo Fisher Scientific Inc. (NYSE:TMO) is recognized as one of the top life sciences stocks to buy according to hedge funds, with analysts maintaining positive ratings and price targets [1][3] Financial Performance - The company reported a revenue growth of 3.91% over the past twelve months, achieving total revenue of $44.56 billion [2] - Management provided guidance for organic growth in 2026, forecasting a range of approximately 3–6%, with an initial lean towards the lower end of this range, indicating a cautious but stable outlook [2] Analyst Ratings - Daniel Arias from Stifel Nicolaus maintained a Buy rating on TMO with a price target of $700, highlighting a strong finish to 2025 and a solid Q4 performance [1] - Catherine Schulte from Baird raised the price target from $645 to $653 while maintaining an Outperform rating, reflecting a positive revision of their model following the fourth-quarter announcement [3] Business Segments - Thermo Fisher Scientific Inc. provides high-end life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products, serving various markets including academics, biotechnology, government, and pharmaceuticals [4]

Core Insights - Thermo Fisher Scientific Inc. (TMO) has a market capitalization of $202.8 billion and provides a range of life sciences solutions and services [1] - Over the past 52 weeks, TMO shares have declined by 2.4%, underperforming the S&P 500 Index, which gained 14.4% [1] - Year-to-date, TMO stock is down 6.8%, while the S&P 500 has risen by 1.4% [1] Performance Comparison - TMO has also underperformed the State Street Health Care Select Sector SPDR ETF (XLV), which increased by 6.2% over the past 52 weeks [2] - On January 29, TMO shares fell by 2.6% despite reporting better-than-expected Q4 results, with revenue of $12.2 billion and adjusted EPS of $6.57, both exceeding analyst estimates [4] - The company's revenue grew by 7.2% year-over-year, while adjusted EPS increased by 7.7% [4] Financial Outlook - Analysts project TMO's EPS to grow by 7.8% year-over-year to $24.65 for fiscal 2026 [5] - TMO has a strong earnings surprise history, exceeding consensus estimates in the last four quarters [5] - Among 23 analysts covering TMO, the consensus rating is a "Strong Buy," with 18 "Strong Buy," 2 "Moderate Buy," and 3 "Hold" ratings [5] Analyst Ratings and Price Targets - The configuration of analyst ratings has become more bullish, with 16 analysts suggesting a "Strong Buy" rating [7] - JPMorgan Chase & Co. maintained a "Buy" rating on TMO with a price target of $710, indicating a potential upside of 31.5% [7] - The mean price target is $662.95, representing a 22.8% premium, while the highest price target of $750 suggests a potential upside of 38.9% [7]

Core Insights - Thermo Fisher Scientific Inc. (TMO) is a leading provider of life sciences solutions, analytical instruments, specialty diagnostics, laboratory products, and biopharma services, with a market cap of $218.2 billion [1] Financial Performance Expectations - Analysts expect TMO to report a profit of $6.44 per share for Q4 2025, reflecting a 5.6% increase from $6.10 per share in the same quarter last year [2] - For the full fiscal year 2025, TMO's EPS is projected to be $22.74, up 4% from $21.86 in fiscal 2024, and is expected to rise to $24.56 in fiscal 2026, an 8% year-over-year increase [3] Stock Performance - TMO stock has underperformed the S&P 500 Index, which gained 15.7% over the past 52 weeks, with TMO shares increasing by only 11.2% during the same period [4] - The stock also lagged behind the Health Care Select Sector SPDR Fund's 12.1% returns in the same timeframe [4] Market Challenges - The underperformance of TMO is attributed to weaknesses in China, pricing pressures, and cautious spending from academic and government sectors, with diagnostics in China still struggling [5] - While Europe shows modest improvement and the U.S. market remains stable but uncertain, these factors have impacted TMO's growth [5] Recent Earnings Report - On October 22, TMO shares rose by 1.7% following the release of Q3 results, where the adjusted EPS of $5.79 exceeded Wall Street's expectations of $5.50, and revenue reached $11.1 billion, surpassing the forecast of $10.9 billion [5] Analyst Ratings - The consensus opinion among analysts on TMO stock is bullish, with a "Strong Buy" rating from 18 out of 23 analysts, while two suggest a "Moderate Buy" and three give a "Hold" rating [6] - The average analyst price target for TMO is $636.90, indicating a potential upside of 8.9% from current levels [6]

Core Insights - The Artisan Value Fund's third-quarter 2025 performance was positive, with returns of 0.83% for Investor Class ARTLX, 0.91% for Advisor Class APDLX, and 0.90% for Institutional Class APHLX, compared to a 5.33% return for the Russell 1000 Value Index [1] Group 1: Market Context - The equity market rally continued in Q3 2025, driven by strong corporate earnings, increased AI investment, and expectations of economic support from US fiscal policy and lower interest rates [1] Group 2: Company Focus - Thermo Fisher Scientific Inc. - Thermo Fisher Scientific Inc. (NYSE:TMO) is highlighted as a key stock, providing life sciences solutions, analytical instruments, specialty diagnostics, laboratory products, and biopharma services [2] - The stock experienced a one-month return of -0.75% but gained 11.93% over the last 52 weeks, closing at $580.74 per share on December 26, 2025, with a market capitalization of $218.19 billion [2] - Thermo Fisher was one of the top contributors to returns in Q3, alongside Lam Research and ASML, following purchases made during a market downturn [3]

Group 1: Market Overview - The S&P 500 Index experienced a significant surge in Q3 2025, driven by investor optimism due to expectations of monetary easing, strong consumer demand, and solid corporate earnings [1] - The Parnassus Core Equity Fund (Investor Shares) returned 2.57% in Q3 2025, underperforming the S&P 500 Index, which returned 8.12% [1] - Year-to-date, the fund's return was 9.89%, compared to 14.83% for the S&P 500 Index [1] Group 2: Company Focus - Thermo Fisher Scientific Inc. - Thermo Fisher Scientific Inc. (NYSE:TMO) is highlighted as a key stock in the Parnassus Core Equity Fund's Q3 2025 investor letter, offering a range of life sciences solutions and services [2][3] - The stock of Thermo Fisher Scientific Inc. had a one-month return of -3.69% but gained 8.83% over the last 52 weeks, closing at $575.70 per share with a market capitalization of $216.3 billion on December 22, 2025 [2] - The company recovered from being oversold earlier in the year, supported by favorable financial results and guidance that exceeded expectations [3] Group 3: Investment Sentiment - Thermo Fisher Scientific Inc. ranked 26th on the list of the 30 Most Popular Stocks Among Hedge Funds, with 121 hedge fund portfolios holding the stock at the end of Q3 2025, an increase from 117 in the previous quarter [3] - While acknowledging the potential of Thermo Fisher Scientific Inc. as an investment, the company believes that certain AI stocks may offer greater upside potential and carry less downside risk [3]

Core Insights - Polen Capital's "Polen Focus Growth Strategy" reported a gross return of 3.34% and a net return of 3.14% for Q3 2025, underperforming the Russell 1000 Growth Index at 10.51% and the S&P 500 Index at 8.12% [1] - The equity market's strong performance was attributed to enthusiasm for generative AI and strength in the semiconductor sector, alongside positive economic surprises and better-than-expected corporate earnings [1] Company-Specific Insights - Thermo Fisher Scientific Inc. (NYSE:TMO) was highlighted as a key stock, with a one-month return of 9.12% but a 52-week loss of 12.65%, closing at $524.58 per share with a market capitalization of $198.088 billion on October 13, 2025 [2] - Polen Focus Growth Strategy eliminated its position in Thermo Fisher Scientific to fund the purchase of Uber, citing ongoing macro, policy, and funding headwinds that are expected to persist [3] - Thermo Fisher Scientific's revenue grew 3% to $10.85 billion in Q2, and it ranked 26th among the 30 most popular stocks among hedge funds, with 117 hedge fund portfolios holding its stock at the end of Q2 [4]

Core Insights - Douglas Lane & Associates has increased its investment in Thermo Fisher Scientific by purchasing 16,745 shares valued at approximately $7.79 million, bringing its total holdings to 216,276 shares [2][11] - Following this purchase, Thermo Fisher Scientific accounts for 1.5% of the fund's reportable assets under management as of September 30, 2025 [3] Company Overview - Thermo Fisher Scientific reported a total revenue of $43.21 billion and a net income of $6.58 billion for the trailing twelve months [4] - The company has a dividend yield of 0.32% and its stock price was $534.68 as of October 9, 2025, reflecting a 12% decline over the past year [3][4] Business Performance - Thermo Fisher achieved a 3% revenue growth to $10.9 billion in its fiscal second quarter, with a 6% year-over-year increase in diluted earnings per share (EPS) to $4.28 [13] - The company has raised its fiscal guidance for 2025 to approximately $44 billion in sales, up from $42.9 billion the previous year [14] Investment Rationale - The current price-to-earnings (P/E) ratio of Thermo Fisher is lower than it was a year ago, suggesting that the stock is more attractively valued now [12] - The combination of rising revenue, increasing EPS, and a reasonable P/E ratio positions Thermo Fisher stock as a compelling buy opportunity [14]

Market Overview - The stock market experienced significant volatility in Q2 2025, with the S&P 500 reaching an all-time high by the end of June [1] - The market saw a drop of 7% from April 2 to April 7 due to the liberation day tariff announcement, followed by a rebound of over 22% from the April 7 low through the end of June [1] - The Russell 1000 Growth returned 17.8% and the S&P 500 returned 10.9% in the quarter, with large caps significantly outperforming small caps and growth outperforming value [1] Renaissance Large Cap Growth Strategy Performance - The strategy outperformed the S&P 500 Index but underperformed the Russell 1000 Growth benchmark [1] Company Focus: Thermo Fisher Scientific Inc. - Thermo Fisher Scientific Inc. (NYSE:TMO) was highlighted as an underperformer, with a one-month return of -0.11% and a 52-week loss of 21.70% [2] - As of September 09, 2025, Thermo Fisher's stock closed at $487.65 per share, with a market capitalization of $182.859 billion [2] - The company reported solid operating results but saw a decline of 18.5% in its stock price, attributed to lowered full-year guidance due to tariff-related macro weakness and uncertainty regarding NIH funding delays impacting academic and government customers [3]